BRAF V600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis

References

• Willman CL, Busque L, Griffith BB, Favara BE, McClain KL, Duncan MH, Gilliland DG. Langerhans'-cell histiocytosis (histiocytosis X)–a clonal proliferative disease. N Engl J Med 1994; 331:154-60; PMID:8008029; http://dx.doi.org/10.1056/NEJM199407213310303
   PubMed Web of Science ®Google Scholar
• Broadbent V, Egeler RM, Nesbit MJ. Langerhans cell histiocytosis–clinical and epidemiological aspects. Br J Cancer Suppl 1994; 23:S11-6; PMID:8075001
   PubMedGoogle Scholar
• Arico M, Egeler RM. Clinical aspects of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12:247-58; PMID:9561898; http://dx.doi.org/10.1016/S0889-8588(05)70508-6
   PubMed Web of Science ®Google Scholar
• Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010; 116:1919-23; PMID:20519626; http://dx.doi.org/10.1182/blood-2010-04-279083
   PubMed Web of Science ®Google Scholar
• Bubolz AM, Weissinger SE, Stenzinger A, Arndt A, Steinestel K, Bruderlein S, Cario H, Lubatschofski A, Welke C, Anagnostopoulos I et al. Potential clinical implications of BRAF mutations in histiocytic proliferations. Oncotarget 2014; 5:4060-70; PMID:24938183; http://dx.doi.org/10.18632/oncotarget.2061
   PubMed Web of Science ®Google Scholar
• Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 2010; 18:884-901; PMID:20627072; http://dx.doi.org/10.1016/j.devcel.2010.05.012
   PubMed Web of Science ®Google Scholar
• Senechal B, Elain G, Jeziorski E, Grondin V, Patey-Mariaud DSN, Jaubert F, Beldjord K, Lellouch A, Glorion C, Zerah M et al. Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. Plos Med 2007; 4:e253; PMID:17696642; http://dx.doi.org/10.1371/journal.pmed.0040253
   PubMedGoogle Scholar
• Coury F, Annels N, Rivollier A, Olsson S, Santoro A, Speziani C, Azocar O, Flacher M, Djebali S, Tebib J et al. Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat Med 2008; 14:81-7; PMID:18157139; http://dx.doi.org/10.1038/nm1694
   PubMed Web of Science ®Google Scholar
• Leslie C, Bowyer SE, White A, Grieu-Iacopetta F, Trevenen M, Iacopetta B, Amanuel B, Millward M. FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor. Pathology 2015; 47:557-63; PMID:26308130; http://dx.doi.org/10.1097/PAT.0000000000000314
   PubMed Web of Science ®Google Scholar
• Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid 2014; 24:1385-93; PMID:24955518; http://dx.doi.org/10.1089/thy.2014.0134
   PubMed Web of Science ®Google Scholar
• Brown NA, Furtado LV, Betz BL, Kiel MJ, Weigelin HC, Lim MS, Elenitoba-Johnson KS. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood 2014; 124:1655-8; PMID:24982505; http://dx.doi.org/10.1182/blood-2014-05-577361
   PubMed Web of Science ®Google Scholar
• Johann DJ, McGuigan MD, Patel AR, Tomov S, Ross S, Conrads TP, Veenstra TD, Fishman DA, Whiteley GR, Petricoin ER, Liotta LA. Clinical proteomics and biomarker discovery. Ann N Y Acad Sci 2004; 1022:295-305; PMID:15251975; http://dx.doi.org/10.1196/annals.1318.045
   PubMed Web of Science ®Google Scholar
• Sahm F, Capper D, Preusser M, Meyer J, Stenzinger A, Lasitschka F, Berghoff AS, Habel A, Schneider M, Kulozik A et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood 2012; 120:e28-34; PMID:22859608; http://dx.doi.org/10.1182/blood-2012-06-429597
   PubMed Web of Science ®Google Scholar
• Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, Idoyaga J, Ruzo A, Lupo PJ, Hicks MJ et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 2014; 211:669-83; PMID:24638167; http://dx.doi.org/10.1084/jem.20130977
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-54; PMID:12068308; http://dx.doi.org/10.1038/nature00766
   PubMed Web of Science ®Google Scholar
• Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006; 203:1651-6; PMID:16801397; http://dx.doi.org/10.1084/jem.20051848
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10:490-500; PMID:20559327; http://dx.doi.org/10.1038/nri2785
   PubMed Web of Science ®Google Scholar
• Gerber AL, Munst A, Schlapbach C, Shafighi M, Kiermeir D, Husler R, Hunger RE. High expression of FOXP3 in primary melanoma is associated with tumour progression. Br J Dermatol 2014; 170:103-9; PMID:24116716; http://dx.doi.org/10.1111/bjd.12641
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002; 99:12293-7; PMID:12218188; http://dx.doi.org/10.1073/pnas.192461099
   PubMed Web of Science ®Google Scholar
• Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006; 66:3381-5; PMID:16585157; http://dx.doi.org/10.1158/0008-5472.CAN-05-4303
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8:793-800; PMID:12091876; http://dx.doi.org/10.1038/nm0902-1039c
   PubMed Web of Science ®Google Scholar
• Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13:84-8; PMID:17159987; http://dx.doi.org/10.1038/nm1517
   PubMed Web of Science ®Google Scholar
• Gatalica Z, Bilalovic N, Palazzo JP, Bender RP, Swensen J, Millis SZ, Vranic S, Von Hoff D, Arceci RJ. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1. Oncotarget 2015; 6:19819-25; PMID:26110571; http://dx.doi.org/10.18632/oncotarget.4378
   PubMed Web of Science ®Google Scholar
• Zhu J, Yamane H, Cote-Sierra J, Guo L, Paul WE. GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res 2006; 16:3-10; PMID:16467870; http://dx.doi.org/10.1038/sj.cr.7310002
   PubMed Web of Science ®Google Scholar
• Michel G, Mirmohammadsadegh A, Olasz E, Jarzebska-Deussen B, Muschen A, Kemeny L, Abts HF, Ruzicka T. Demonstration and functional analysis of IL-10 receptors in human epidermal cells: decreased expression in psoriatic skin, down-modulation by IL-8, and up-regulation by an antipsoriatic glucocorticosteroid in normal cultured keratinocytes. J immunol 1997; 159:6291-7; PMID:9550434
   PubMed Web of Science ®Google Scholar
• De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011; 208:469-78; PMID:21339327; http://dx.doi.org/10.1084/jem.20101876
   PubMed Web of Science ®Google Scholar
• Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med 2015; 373:726-36; PMID:26287849; http://dx.doi.org/10.1056/NEJMoa1502309
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44; PMID:23724846; http://dx.doi.org/10.1056/NEJMoa1305133
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
   PubMed Web of Science ®Google Scholar
• Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013; 19:1225-31; PMID:23307859; http://dx.doi.org/10.1158/1078-0432.CCR-12-1630
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Mok S, Homet MB, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med 2015; 7:241r-279r; PMID:25787767; http://dx.doi.org/10.1126/scitranslmed.aaa4691
   PubMedGoogle Scholar
• Azim HJ, Peccatori FA, Brohee S, Branstetter D, Loi S, Viale G, Piccart M, Dougall WC, Pruneri G, Sotiriou C. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res 2015; 17:24; PMID:25849336; http://dx.doi.org/10.1186/s13058-015-0538-7
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563-7; PMID:25428504; http://dx.doi.org/10.1038/nature14011
   PubMed Web of Science ®Google Scholar